News - Appointments

Anderson Gaweco, an immunologist with academic and industry experience, has joined APEIRON Biologics AG as chief medical and scientific officer. In this role he will oversee the discovery and clinical development of new therapies for cancer.

Switzerland-based Kuros Biosciences AG has appointed Pascal Longlade as chief medical officer to help oversee the development of its products for tissue repair and regeneration. Kuros was created in 2015 from a reverse merger with the asthma drug developer Cytos Biotechnology Ltd.

Swedish Orphan Biovitrum AB (Sobi) has appointed Anne Marie de Jonge Schuermans as head of its new technical operations organisation, bringing together manufacturing, procurement and environment and safety operations.

Gerald Cagle, an experienced pharmaceutical executive, has joined the board of directors of Eyevensys SAS, which is developing non-viral gene therapies for eye diseases.

Novartis has appointed Klaus Moosmayer, a lawyer, as chief ethics, risk and compliance officer to oversee all of the company’s risk management functions, effective 1 December.

Namir Hassan, a T cell biologist, has joined Zelluna Immunotherapy AS as chief scientific officer to help oversee development of the company’s portfolio of T cell receptors (TCR) derived from cancer patients.

Tris Vaughan, an executive at MedImmune, has joined the scientific advisory board of Sphere Fluidics Ltd, a UK developer of single cell analysis systems for drug discovery and development.

GlaxoSmithKline Plc has appointed Iain Mackay to become its new chief financial officer effective 14 January 2019 succeeding Simon Dingemans who will retire in May 2019.

Belgium-based Celyad SA has appointed Filippo Petti as chief financial officer, effective 3 September, succeeding Patrick Jeanmart who is stepping down from the position.

Cell Medica Ltd has appointed Chris Nowers as its new chief executive to succeed the founder and CEO Gregg Sando who has stepped down to pursue new ventures.